25-hydroxyvitamin D3-1.alpha.-hydroxylase and DNA encoding the hydroxylase
US6274359A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jul 8, 1998 |
| Grant date | Aug 14, 2001 |
| Priority date | — |
| Expiry date | Jul 8, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a polypeptide having 25-hydroxyvitamin D.sub.3 -1.alpha.-hydroxylase activity, being useful for the prevention, diagnosis and therapeutic treatment of adult diseases such as osteoporosis induced by the decrease of active type vitamin D.sub.3 and catalyzing the final stage of vitamin D.sub.3 activation; and the gene encoding the polypeptide. In accordance with the present invention, the following can be provided; a polypeptide having 25-hydroxyvitamin D.sub.3 -1.alpha.-hydroxylase activity, DNA encoding the polypeptide, a recombinant DNA prepared by inserting the DNA in a vector, a transformant carrying the recombinant DNA, a method for preparing 25-hydroxyvitamin D.sub.3 -1.alpha.-hydroxylase by using the transformant, a method for preparing 1.alpha., 25-dihydroxyvitamin D.sub.3 comprising using the polypeptide having 25-hydroxyvitamin D.sub.3 -1.alpha.-hydroxylase activity, and an antibody recognizing the polypeptide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.